Funds and ETFs Myriad Genetics, Inc.




Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 03:59:51 2024-02-22 pm EST 5-day change 1st Jan Change
23.1 USD +0.81% Intraday chart for Myriad Genetics, Inc. -2.10% +20.66%
Myriad Genetics, a genetic testing and precision medicine company. The Company provides testing that helps assess an individual's risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. It has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
23.1 USD
Average target price
22.5 USD
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Myriad Genetics, Inc. - Nasdaq
  4. Funds and ETFs Myriad Genetics, Inc.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance